Health research collaborations mean sharing data – we can deliver faster if we identify and remove obstacles early, write IHI's Niklas Blomberg and EFPIA's Magda Chlebus.
Setting up a non-profit association is one way to ensure the sustainability of EU-funded project results. Two Innovative Medicines Initiative projects share their experiences as they navigate this process.
A new clinical trial testing the best administration route for an experimental arthritis treatment is using outcome measures established by IMI project RT-Cure to evaluate its performance.
A nasal vaccine against pertussis that was tested using a model and cell bank created by IMI project PERISCOPE is entering the final phases of clinical trials.
The Innovative Medicines Initiative project published a series of recommendations for how the regulatory process in the EU for approving cell and gene therapies could be sped up
The news means we are one step closer to treating adult patients with complicated intra-abdominal and urinary tract infections and hospital-acquired pneumonias caused by Gram-negative bacteria
The findings, published in Nature Aging, illustrate the benefit of large datasets such as the EPND database to find important patterns in biological data.
Findings from Innovative Medicines Initiative project BigData@Heart underscore the importance of accounting for sex-based differences in medical research.
A new non-profit company is delivering fully characterised, lab-based paediatric tumour models for testing potential cancer therapies, thanks to the IMI ITCC-P4 project’s results.
Results from IMI project COMBACTE-CARE show that – if approved – a new combination of drugs could help in the fight against some of the most dangerous drug-resistant bacteria.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.